The Filing Desk

OraSure Technologies

OSUR · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OSUR · Last close · November 19, 2026
$3.61
Value OraSure Technologies yourself

OraSure Technologies' revenue fell 38.1% to $115 million in fiscal 2025. Its operating margin was −62.6%, down from −15.2% a year earlier. Free cash flow was −$53 million, against $24 million a year earlier. It paid out $15 million in dividends and buybacks. The diluted share count fell 1.3%.

ORASURE TECHNOLOGIES, INC Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001116463-26-000016 Updated
Revenue
$115M
38.1%
Operating margin
−62.6%
47.4 pts
Net income
−$69M
 
Free cash flow
−$53M
$24M a year earlier
Return on equity
−18.3%
13.7 pts
Market cap
$249M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Diluted earnings per share for fiscal 2020 is left blank: the SEC's structured data gives it the opposite sign from net income per share.

Charts show fiscal years, from the 10-K filings.

What OraSure Technologies does

OraSure Technologies (OTI) makes rapid diagnostic tests and devices for collecting samples such as saliva and urine. Its tests detect HIV, hepatitis C, syphilis, sickle cell disease and COVID-19, and give results at the point of care. It sells them in the United States and abroad to clinical laboratories, hospitals, clinics, community groups, public health bodies, distributors, government agencies and doctors' offices. Its HIV and COVID-19 tests are also sold to consumers over the counter in the U.S., and its HIV and hepatitis C products are sold as self-tests in several other countries.

It has two main lines of business: diagnostics products, and sample management solutions. Sample management products are used by clinical laboratories, direct-to-consumer laboratories, researchers, drug companies and animal health companies. Its principal products include the OraQuick HIV tests and the InteliSwab COVID-19 test. It also sells to the U.S. government and says it expects InteliSwab revenue to keep declining.

In November 2025 it bought BioMedomics, whose SickleSCAN test is sold outside the U.S. In December 2025 it asked the FDA to clear a molecular self-test for chlamydia and gonorrhea and an at-home urine collection device. As of December 31, 2025, it had 500 full-time employees.

Its biggest risks, as it describes them

  • Falling sales of its InteliSwab COVID-19 test, which it expects to continue.
  • Reliance on U.S. government funding and customers, with audits, contract limits and ordering that can change.
  • Increasing competition from other diagnostic test and sample collection providers.
  • Some products depend on a sole-source supplier, and manufacturing problems could stop deliveries.
  • Its results may suffer if customers do not keep adopting oral fluid testing and collection products.
From OraSure Technologies's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2023, earnings per share grew 10.9% a year and net income 15.4% a year, as new shares raised the share count by 32% and diluted each share's earnings. OraSure Technologies then lost money in fiscal 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments153111290268199
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.4x4.7x9.8x9.9x6.6x
Quick ratio3.6x3.3x8.6x8.9x5.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project OraSure Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What OraSure Technologies says to expect

  • Full year 2027: total revenue growthThe Company expects to see an acceleration of year-over-year growth in total revenues for the full year 2027 as compared to the full year 2026.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $456,495 of OraSure Technologies shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 14, 2026Steven Kyle BoydDirectorBought25,000$2.99$74,750Form 4
May 13, 2026Steven Kyle BoydDirectorBought25,000$3.02$75,500Form 4
May 12, 2026Steven Kyle BoydDirectorBought25,000$2.98$74,500Form 4
Mar 20, 2026Manner Carrie EglintonPresident & CEO, DirectorBought plan32,300$2.93$94,639Form 4
Mar 13, 2026Manner Carrie EglintonPresident & CEO, DirectorBought plan22,022$3.00$66,066Form 4
Mar 13, 2026Kenneth J McGrathChief Financial OfficerBought plan22,021$3.00$66,063Form 4
Nov 28, 2025Nancy J GaglianoDirectorBought2,100$2.37$4,977Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 4038.1%−41.5%−84.4%
Altman Z''13.279.226.76
Accruals ratio−19.0%−9.7%−4.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassFailFail
Cash from operations is positivePassPassFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't riseFailFailPass
Gross margin rosePassPassFail
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put OraSure Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
OraSure TechnologiesFY25−38.1%−62.6%−46.3%———
Anika TherapeuticsFY25−5.9%−9.8%3.9%———Compare
Outset MedicalFY255.1%−55.8%−39.4%−88.0%—6Compare
OwletFY2535.4%−7.8%−10.5%——5Compare
Sanara MedTechFY2519.0%7.1%2.1%13.0%2.6x3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue128167182155172234388406186115
Revenue growth7.1%30.3%8.8%−14.9%11.1%36.1%65.8%4.6%−54.2%−38.1%
Gross profit8899114951021181481727948
Research and development10131620313436342642
Operating income20402819−5−10−2233−28−72
Net income20312017−15−23−1754−20−69
Diluted EPS (US$)0.350.510.330.27—−0.32−0.240.72−0.26−0.94
Diluted shares (millions)56616262687272747474
Cash flow
Cash from operations252839106−35−4714227−49
Capital expenditure446927227644
Free cash flow2024330−21−57−5413624−53
Dividends paid0000000000
Share buybacks31442220015
Acquisitions00024300054
Stock-based compensation671547812111210
Balance sheet at fiscal year end
Cash and short-term investments119154157156209153111290268199
Debt incl. finance leases——————————
Total assets208296316349454461444483480403
Total liabilities22383242568080526962
Shareholders' equity186258283307399380364431410341
Margins and ratios
Gross margin68.7%59.2%62.5%61.2%59.3%50.3%38.3%42.3%42.7%41.9%
Operating margin15.8%24.1%15.6%12.0%−3.0%−4.3%−5.7%8.1%−15.2%−62.6%
Net margin15.4%18.5%11.2%10.8%−8.7%−9.8%−4.4%13.2%−10.5%−59.8%
Free cash flow margin15.8%14.3%18.0%0.3%−12.2%−24.5%−13.9%33.5%12.7%−46.3%
Rule of 40 (growth + FCF margin)22.9%44.6%26.8%−14.6%−1.1%11.6%51.9%38.1%−41.5%−84.4%
Return on capital——————————
Return on equity11.4%13.9%7.5%5.6%−4.2%−5.9%−4.6%13.5%−4.6%−18.3%
Return on assets9.9%12.3%6.7%5.0%−3.7%−5.0%−3.8%11.6%−4.0%−15.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: OraSure Technologies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with OraSure Technologies.